Jean-Francois Pariseau

Unrepentant entrepreneur. Unrepentant investor. Co-founder of Amplitude. Led investments at BDC Capital’s Healthcare Fund and CDP Capital Technology Ventures. Lived the start-up dream, twice.

Lahav Gil

Lahav Gil is the CEO of RelayMedical, managing a portfolio of technologies and companies in the medtech, health IT and medications management marketplace. Lahav Founded/co-founded 6 companies. He has contributed to over 200 technology-product launches and several game-changing innovations for Canadian startups.

Maha Katabi

Maha joined Sofinnova as a Partner, where she focuses on development stage investments in therapeutics. Previously, Maha was a Managing Partner of Oxalis Capital, a Partner at Sectoral Asset Management and Vice-President at Ventures West Management, a venture capital firm focusing on technology and life sciences in Canada and the US.

Youssef Bennani

​

Dr. Youssef Bennani, Venture Partner of adMare BioInnovations is responsible for translating academic research into new companies of scale, to deploying a combination of physical infrastructure, scientific and business expertise, and capital, to help existing companies scale-up. Youssef also serves as the Chairman of the Board of Domain Therapeutics (France & Canada), and is an independent Board member of Bellus Health. 

RBC Ventures

​

Speaker to be confirmed

Anthony Ferrara

 

Anthony is the Associate Vice President, Commercial Banking Healthcare & Lifesciences for National Bank. Anthony covers Canada’s leading commercial banking team exclusively focused on high-growth opportunities in the Healthcare & Lifesciences space. The platform provides tailored solutions with respect to debt raises in M&A transactions, Healthcare & Lifesciences Private Equity and Sponsor coverage, growth and expansion capital structures, cash management, deposits and advisory services. 

​

Patrice Allibert

​

Dr Patrice Allibert is an accomplished business man, bringing a Molecular Diagnostic Company (GenePOC) from an early stage all the way to a liquidity event. Prior to this, he was Vice President R&D Molecular and Strategic Innovation for Molecular Infectious Diseases and he worked with Merial as Corporate Director for Bioanalytical Development.

Guy Barthell

​

Gur Barthell posesses over 30 years of experience in management and strategic consulting. He specializes in strategic planning, commercialization strategies, merger and acquisitions and due diligence. 

Louis Cossette

​

Trained as a scientist (Cellular and Molecular Biology), Louis  joined Deloitte to share his experience with companies who want to optimize their R&D using all the help available.